To enhance the translational relevance of our findings, we developed anorally bioavailable SMARCA2/4 PROTAC degrader, named AU-24118, which exhibitsenhanced pharmacokinetic (PK) properties compared to AU-15330.29 AU-24118 effectively degradedSMARCA2, SMARCA4, and PBRM1, and displayed a preferential growth inhibitoryeffect for SCLC-P cell lines compared to SCLC-A, SCLC-N, and SCLC-Y cell lines(Figures S3G andS3H). This evidence concerns the gene SMARCA4 and small cell lung carcinoma.